叶酸向的混合多发性小细胞,用于输送三托利德
Meizhen Yin1, Xinying Zhang1, Tongguang Zhang1
1Medical College, Inner Mongolia Minzu University, Tongliao 028043, China.
Polymers
|January 8, 2025
概括
这项研究开发了叶酸修饰的混合多元 (FA-F-127/F-68-TPL) 用于向的三类 (TPL) 输送,显示肝癌细胞细胞毒性增强和小鼠瘤生长减少.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战,需要创新的治疗策略.
- 托利 (TPL) 具有强大的抗癌性质,但具有不良的溶解性和全身毒性.
- 开发有效的药物输送系统对于提高TPL的治疗指数至关重要.
研究的目的:
- 开发和表征叶酸修饰混合多元 (FA-F-127/F-68-TPL) 作为三类 (TPL) 的理想输送系统.
- 评估FA-F-127/F-68-TPL对肝细胞癌的体内细胞毒性,细胞吸收和体内抗瘤功效.
- 评估开发的纳米细胞的向潜力和药物动力学特性.
主要方法:
- 使用薄膜水化方法制备FA-F-127/F-68-TPL.
- 使用扫描电子显微镜 (SEM) 和原子力显微镜 (AFM) 的微粒特征.
- 在HepG2细胞的体外细胞毒性测定,使用尼罗河红色 (Nr) 作为模型药物的细胞吸收研究,以及在裸体小鼠模型中的体内抗瘤功效研究.
主要成果:
- FA-F-127/F-68-TPL小粒呈现球形形状,平均颗粒大小为30.7 nm.
- 与裸体TPL相比,FA-F-127/F-68-TPL显示出对HepG2细胞显著增强的细胞毒性.
- 在体内研究显示了显著抑制移植瘤生长和有效的脏分泌纳米细胞.
结论:
- FA-F-127/F-68-TPL是TPL的一个有前途的纳米载体,具有低成本,良好的生物特性和主动/被动准的优势.
- 该系统对肝癌细胞表现出显著的细胞毒性,并显著抑制瘤生长.
- 高效的脏分泌可以防止药物在循环过程中释放,最大限度地减少对正常组织的损伤,并突出其作为先进的抗瘤药物递送系统的潜力.
相关概念视频
Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Bioavailability Enhancement: Drug Permeability Enhancement
351
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
351
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
332
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
332
Modified-Release Drug Delivery Systems: Site-Targeted
161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Site-Targeted Drug Delivery Systems: Polymeric Carriers
159
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
159


